Hitoshi Inari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hitoshi Inari has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Satoru Shimizu
Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 232 Nakao, Asahi-ku, Yokohama, Japan
5 shared publicationsTakashi Yamanaka
Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 232 Nakao, Asahi-ku, Yokohama, Japan
5 shared publicationsTatsuya Yoshida
Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 232 Nakao, Asahi-ku, Yokohama, Japan
4 shared publicationsAyumi Yamanaka
Department of Surgery, Yokohama City University, 39 Fukuura, Kanazawa-ku, Yokohama, Japan
3 shared publicationsHirotaka Nakayama
Department of Surgery, Yokohama City University, 39 Fukuura, Kanazawa-ku, Yokohama, Japan
3 shared publicationsMunetaka Masuda
Department of Surgery, Yokohama City University, 39 Fukuura, Kanazawa-ku, Yokohama, Japan
3 shared publications
Latest Publications
- Open Access
- 10 January 2018
- Published by Springer Nature in Breast Cancer
- Vol. 25 (2) , 257-258
Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women
In the original publication of this article, Table 1 was published incorrectly with rows out of order under “Distant metastasis ( n, %)”.
- 10 January 2018
- Published by Springer Nature in Breast Cancer
- Vol. 25 (2) , 257-258
Open AccessCorrection to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women
In the original publication of this article, Table 1 was published incorrectly with rows out of order under “Distant metastasis ( n, %)”.
- 19 April 2017
- Published by Springer Nature in Breast Cancer
- Vol. 24 (6) , 748-755
Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer
Surgical biopsy of metastatic lesions followed by pathological confirmation for the investigation of biomarkers is occasionally proposed as an effective strategy in the treatment of metastatic breast cancer. However, few reports have examined Ki-67 immunohistochemical expression in distant metastatic lesions of breast cancer patients. This study aimed to investigate the clinicopathological significance of subtypes and Ki-67 immunohistochemical expression in metastatic breast cancer lesions.
- 19 April 2017
- Published by Springer Nature in Breast Cancer
- Vol. 24 (6) , 748-755
Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer
Surgical biopsy of metastatic lesions followed by pathological confirmation for the investigation of biomarkers is occasionally proposed as an effective strategy in the treatment of metastatic breast cancer. However, few reports have examined Ki-67 immunohistochemical expression in distant metastatic lesions of breast cancer patients. This study aimed to investigate the clinicopathological significance of subtypes and Ki-67 immunohistochemical expression in metastatic breast cancer lesions.
- Open Access
- 27 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-14
Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
- 27 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-14
Open AccessExpression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e23227
Correlation of expression of enhancer of zeste homolog 2 with the survival outcome in patients with metastatic breast cancer using primary and paired metastatic lesions.
E23227 Background: Enhancer of zeste homolog 2 (EZH2), a Polycomb group protein, has been linked to aggressive breast cancer. Few reports have examined EZH2 expression in metastatic lesions of breast cancer patients. Therefore, the purpose of this study was to investigate the clinicopathological significance of EZH2 expression in metastatic breast cancers (MBCs). Methods: We retrospectively studied the surgical specimens of primary breast cancer (PBC) tumors and their corresponding metastatic lesions from patients (n= 96) who underwent surgery for the PBC tumor between December 1977 and March 2013. Tissue microarrays (TMAs) and whole tissue sections were constructed, using primary and metastatic lesions, and stained with antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and EZH2. We examined the correlations between ER, PR, HER2, Ki-67, and EZH2 expression, and the clinicopathological characteristics and outcome measures of the patients. Results: Compared to primary lesions, metastatic lesions exhibited significantly higher levels of expression of Ki-67 (75.0% vs. 42.7%, P= 0.01) and EZH2 (71.9% vs. 56.3%, P< 0.0001). Ki-67 expression was significantly highly correlated with EZH2 expression in primary lesions and metastatic lesions. Patients expressing high levels of EZH2 in primary lesions were not associated with poorer overall survival (OS) outcomes after recurrence than patients expressing low levels of EZH2 in primary lesions (P = 0.096), whether patients expressing high levels of EZH2 in metastatic lesions were associated with significantly than patients expressing low levels of EZH2 (P = 0.014). High levels of EZH2 expression in metastatic lesions were independently associated with poorer OS outcomes after recurrence. Conclusions: We show that high EZH2 expression levels in metastatic lesions are independently more associated with poorer OS outcomes after recurrence than primary lesions.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e23227
Correlation of expression of enhancer of zeste homolog 2 with the survival outcome in patients with metastatic breast cancer using primary and paired metastatic lesions.
E23227 Background: Enhancer of zeste homolog 2 (EZH2), a Polycomb group protein, has been linked to aggressive breast cancer. Few reports have examined EZH2 expression in metastatic lesions of breast cancer patients. Therefore, the purpose of this study was to investigate the clinicopathological significance of EZH2 expression in metastatic breast cancers (MBCs). Methods: We retrospectively studied the surgical specimens of primary breast cancer (PBC) tumors and their corresponding metastatic lesions from patients (n= 96) who underwent surgery for the PBC tumor between December 1977 and March 2013. Tissue microarrays (TMAs) and whole tissue sections were constructed, using primary and metastatic lesions, and stained with antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and EZH2. We examined the correlations between ER, PR, HER2, Ki-67, and EZH2 expression, and the clinicopathological characteristics and outcome measures of the patients. Results: Compared to primary lesions, metastatic lesions exhibited significantly higher levels of expression of Ki-67 (75.0% vs. 42.7%, P= 0.01) and EZH2 (71.9% vs. 56.3%, P< 0.0001). Ki-67 expression was significantly highly correlated with EZH2 expression in primary lesions and metastatic lesions. Patients expressing high levels of EZH2 in primary lesions were not associated with poorer overall survival (OS) outcomes after recurrence than patients expressing low levels of EZH2 in primary lesions (P = 0.096), whether patients expressing high levels of EZH2 in metastatic lesions were associated with significantly than patients expressing low levels of EZH2 (P = 0.014). High levels of EZH2 expression in metastatic lesions were independently associated with poorer OS outcomes after recurrence. Conclusions: We show that high EZH2 expression levels in metastatic lesions are independently more associated with poorer OS outcomes after recurrence than primary lesions.
- 11 February 2016
- Published by Springer Nature in Breast Cancer
- Vol. 24 (1) , 98-103
A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women
Several studies from other countries have reported that patients with screen-detected breast cancer have better survival than those with symptomatic breast cancer. However, no such comparison has been performed in Japan. Therefore, we aimed to compare the clinicopathological characteristics and survival rates between symptomatic and screen-detected breast cancer in Japanese women. From January 2000 to December 2004, 977 and 182 women with symptomatic or screen-detected breast cancer, respectively, underwent surgery at a single Japanese hospital. We retrospectively reviewed these patients’ clinicopathological data. Likelihood of death was estimated using the Kaplan–Meier method and the log-rank test. Multivariate analysis including mode of detection, tumor size, lymph node status, hormone receptor status, and adjuvant therapy administration was performed using the Cox proportional hazards model. Screen-detected breast cancer was associated with increased rate of breast-conserving surgery, non-invasive carcinoma, smaller tumor size, decreased lymph node involvement, increased hormone receptor positivity, and decreased adjuvant chemotherapy administration. Compared to women with symptomatic tumors, those with screen-detected tumors had improved overall and breast cancer-specific survival rates. Factors associated with survival in univariate analysis were screen detection, tumor size, lymph node status, progesterone receptor status, and adjuvant chemotherapy administration. Breast cancer screening in Japanese women has led to increases in the rates of breast-conserving surgery, hormone receptor positivity, and survival rates along with reductions in axillary lymph node dissection and adjuvant chemotherapy administration.
- 11 February 2016
- Published by Springer Nature in Breast Cancer
- Vol. 24 (1) , 98-103
A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women
Several studies from other countries have reported that patients with screen-detected breast cancer have better survival than those with symptomatic breast cancer. However, no such comparison has been performed in Japan. Therefore, we aimed to compare the clinicopathological characteristics and survival rates between symptomatic and screen-detected breast cancer in Japanese women. From January 2000 to December 2004, 977 and 182 women with symptomatic or screen-detected breast cancer, respectively, underwent surgery at a single Japanese hospital. We retrospectively reviewed these patients’ clinicopathological data. Likelihood of death was estimated using the Kaplan–Meier method and the log-rank test. Multivariate analysis including mode of detection, tumor size, lymph node status, hormone receptor status, and adjuvant therapy administration was performed using the Cox proportional hazards model. Screen-detected breast cancer was associated with increased rate of breast-conserving surgery, non-invasive carcinoma, smaller tumor size, decreased lymph node involvement, increased hormone receptor positivity, and decreased adjuvant chemotherapy administration. Compared to women with symptomatic tumors, those with screen-detected tumors had improved overall and breast cancer-specific survival rates. Factors associated with survival in univariate analysis were screen detection, tumor size, lymph node status, progesterone receptor status, and adjuvant chemotherapy administration. Breast cancer screening in Japanese women has led to increases in the rates of breast-conserving surgery, hormone receptor positivity, and survival rates along with reductions in axillary lymph node dissection and adjuvant chemotherapy administration.
- 1 April 2014
- Vol. 41 (4) , 487-9
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
A 75-year-old woman presented to a local doctor with a lump in the right breast. On physical examination, a tumor measuring 24mm was palpable in the BD area of her right breast. Mammography showed category 5 disease, and ultrasonography revealed a tumor measuring 24×16 mm. A mammotome biopsy provided a diagnosis of invasive ductal carcinoma of the breast(ER 7/PgR 4/HER2 1+), and the tumor was classified as stage IIA(T2N0M0)according to the UICC-TNM classification. She was recommended surgery but she rejected this option and underwent hormone therapy with anastrozole (1mg/day). One year and 8months after beginning the treatment, ultrasonography showed the tumor to measure 7.0×5.7 mm, and hormone therapy resulted in a partial response(PR). The patient hoped to undergo an operation, so she was referred to our hospital, and a right partial mastectomy and sentinel node biopsy was performed. A histopathological exami- nation indicated scirrhous carcinoma, 18mm, nuclear grade 1, f, ly1, v0, n0, ER 3/PgR 3/HER2 3+. The curative effect was grade 1a. The tumor had become HER2 positive, so the patient was then administered radiotherapy and trastuzumab and anastrozole as adjuvant therapy. Herein, we report our experience with a case of breast cancer that only became HER2 positive after hormone therapy, and also provide some bibliographic comments on this occurrence.
- 1 April 2014
- Vol. 41 (4) , 487-9
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
A 75-year-old woman presented to a local doctor with a lump in the right breast. On physical examination, a tumor measuring 24mm was palpable in the BD area of her right breast. Mammography showed category 5 disease, and ultrasonography revealed a tumor measuring 24×16 mm. A mammotome biopsy provided a diagnosis of invasive ductal carcinoma of the breast(ER 7/PgR 4/HER2 1+), and the tumor was classified as stage IIA(T2N0M0)according to the UICC-TNM classification. She was recommended surgery but she rejected this option and underwent hormone therapy with anastrozole (1mg/day). One year and 8months after beginning the treatment, ultrasonography showed the tumor to measure 7.0×5.7 mm, and hormone therapy resulted in a partial response(PR). The patient hoped to undergo an operation, so she was referred to our hospital, and a right partial mastectomy and sentinel node biopsy was performed. A histopathological exami- nation indicated scirrhous carcinoma, 18mm, nuclear grade 1, f, ly1, v0, n0, ER 3/PgR 3/HER2 3+. The curative effect was grade 1a. The tumor had become HER2 positive, so the patient was then administered radiotherapy and trastuzumab and anastrozole as adjuvant therapy. Herein, we report our experience with a case of breast cancer that only became HER2 positive after hormone therapy, and also provide some bibliographic comments on this occurrence.
- 1 November 2012
- Vol. 39 (11) , 1675-9
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients. The median number of treatment courses was 6(1-22). Brain metastasis developed in 18 cases(40%), and 19 cases(42.2%)had received previous capecitabine treatment for metastatic breast cancer. The objective response rate(ORR=CR+PR)was 22.2%(10/45), and clinical benefit rate(CR+PR+long SD=24w)was 46.7%(21/45).The median time to progression(TTP)was 24.9 weeks(95% CI: 15.2 -34.6 ), and the median overall survival(OS)was 78.1 weeks(95% CI: 55.7 -100.5)in all 45 cases. The median TTP was significantly longer in patients who had not received capecitabine previously(30 vs 16 weeks, 95% CI: 16.3 -43.7, p=0.0051 ). There was no statistical difference in median OS associated with previous capecitabine exposure(42.7 weeks, 95% CI: 21.4 -64, p=0.057 ). The median TTP was significantly longer in patients who received less than 2 treatment regimens with trastuzumab for MBC rather than 3 regimens more(27.3 vs 16 weeks, p=0.0257 ), but there was no statistical difference in median OS(81 vs 40.9 weeks, p=0.26 ). Lapatinib in combination with capecitabine is likely more useful in patients who are naive to capecitabine, who received less than two regimens for metastatic breast cancer.
- 1 November 2012
- Vol. 39 (11) , 1675-9
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients. The median number of treatment courses was 6(1-22). Brain metastasis developed in 18 cases(40%), and 19 cases(42.2%)had received previous capecitabine treatment for metastatic breast cancer. The objective response rate(ORR=CR+PR)was 22.2%(10/45), and clinical benefit rate(CR+PR+long SD=24w)was 46.7%(21/45).The median time to progression(TTP)was 24.9 weeks(95% CI: 15.2 -34.6 ), and the median overall survival(OS)was 78.1 weeks(95% CI: 55.7 -100.5)in all 45 cases. The median TTP was significantly longer in patients who had not received capecitabine previously(30 vs 16 weeks, 95% CI: 16.3 -43.7, p=0.0051 ). There was no statistical difference in median OS associated with previous capecitabine exposure(42.7 weeks, 95% CI: 21.4 -64, p=0.057 ). The median TTP was significantly longer in patients who received less than 2 treatment regimens with trastuzumab for MBC rather than 3 regimens more(27.3 vs 16 weeks, p=0.0257 ), but there was no statistical difference in median OS(81 vs 40.9 weeks, p=0.26 ). Lapatinib in combination with capecitabine is likely more useful in patients who are naive to capecitabine, who received less than two regimens for metastatic breast cancer.